PharmaShots | Incisive News in 3 Shots

Subscribe Now

Mindmed

MindMed Reports the Results for MM120 in P-IIb Trial and Receives US FDA’s BTD for the Treatment of Generalized Anxiety Disorder (GAD)

MindMed Reports the Results for MM120 in P-IIb Trial and Receives US FDA’s BTD for the Treatment of Generalized Anxiety Disorder (...

March 8, 2024

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

August 29, 2023

MindMed Entered into an Exclusive License Agreement with Catalent for Patented Zydis Fast-Dissolve Technology Incorporated in MM-120

MindMed Entered into an Exclusive License Agreement with Catalent for Patented Zydis Fast-Dissolve Technology Incorporated in MM-1...

August 3, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us